GlassScriptPhysician profile
Yu Lin Lee
NPI 1891086211
$5,330.20
in general payments reported to CMS, 2019-2025
21 companies · $3,746 in 2025
The $3,746 reported for 2025 was more than what 96% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.66 · 2020: $35.21 · 2021: $160 · 2022: $139 · 2023: $250 · 2024: $932 · 2025: $3,746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,200 · Food and Beverage: $728.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,200.00 |
| Food and Beverage | $728.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $4,200.00 | 2024-2025 | Bovine Collagen |
| Mayne Pharma Commercial LLC | $137.14 | 2022-2025 | |
| Hologic Sales and Service, LLC | $133.55 | 2025 | Novasure, Myosure Tissue Removal Device, Fluent Fluid Management System |
| Astellas Pharma US INC | $129.17 | 2023-2025 | Veozah |
| Abbvie INC. | $126.99 | 2020-2023 | |
| Exeltis, USA INC. | $96.95 | 2021-2025 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $95.46 | 2019-2023 | |
| Pfizer INC. | $78.45 | 2021-2024 | |
| Millicent US INC | $52.56 | 2023-2025 | Intrarosa, Femlyv |
| Therapeuticsmd, INC. | $51.41 | 2019-2022 | |
| Organon LLC | $45.83 | 2024-2025 | Nexplanon |
| Sage Therapeutics, LLC | $36.71 | 2025 | Zurzuvae |
| Myovant Sciences INC. | $21.83 | 2021 | |
| Supernus Pharmaceuticals, INC. | $21.42 | 2025 | Qelbree |
| Mylan Pharmaceuticals INC. | $20.33 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $18.09 | 2021 | |
| Aspira Women'S Health INC | $17.42 | 2022 | |
| Coopersurgical, INC. | $16.61 | 2019 | |
| Idorsia Pharmaceuticals US INC | $15.63 | 2024 | Quviviq |
| Medicem INC. | $14.65 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yu Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.